InvestorsHub Logo
Followers 17
Posts 581
Boards Moderated 0
Alias Born 05/18/2018

Re: Investor2014 post# 292429

Monday, 01/11/2021 2:46:05 PM

Monday, January 11, 2021 2:46:05 PM

Post# of 461451
Investor, agree "undisclosed stat sig P value for the primary endpoint" is a problem. I would add, that they had 7 secondary endpoints for this trial and their new trial "TRAILBLAZER-ALZ 2", actually has 9 secondary endpoints!

I would say they are on a better track than the BIIB drug, fudgeomab(can never remember the name).

Also, interesting how the big boys release very little trial results, and we can never get enough.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News